The investigators propose a small pilot proof of concept study to not only prove the
existence of, but also probe the mechanisms underlying cardio-renal effects of empagliflozin
in patients with heart failure. The investigators propose a 50 patient randomized,
double-blind, placebo-controlled crossover study with patients with stable HF, type II
diabetes and an eGFR >45ml/min/1.73 m2 who are chronically receiving loop diuretics.